RT Journal Article
SR Electronic
T1 Metabolomic-based biomarker discovery for non-invasive lung cancer screening: A case study
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 063321
DO 10.1101/063321
A1 Keiron O’Shea
A1 Simon J.S. Cameron
A1 Keir E Lewis
A1 Chuan Lu
A1 Luis AJ Mur
YR 2016
UL http://biorxiv.org/content/early/2016/07/12/063321.abstract
AB Background Lung cancer (LC) is one of the leading lethal cancers worldwide, with an estimated 18.4% of all cancer deaths being attributed to the disease. Despite developments in cancer diagnosis and treatment over the previous thirty years, LC has seen little to no improvement in the overall five year survival rate after initial diagnosis.Methods In this paper, we extended a recent study which profiled the metabolites in sputum from patients with lung cancer and age-matched volunteers smoking controls using flow infusion electrospray ion mass spectrometry. We selected key metabolites for distinguishing between different classes of lung cancer, and employed artificial neural networks and leave-one-out cross-validation to evaluate the predictive power of the identified biomarkers.Results The neural network model showed excellent performance in clas sification between lung cancer and control groups with the area under the receiver operating characteristic curve of 0.99. The sensitivity and specificity of for detecting cancer from controls were 96% and 94% respectively. Furthermore, we have identified six putative metabolites that were able todiscriminate between sputum samples derived from patients suffering small cell lung cancer (SCLC) and non-small cell lung cancer. These metabolites achieved excellent cross validation performance with a sensitivity of 80% and specificity of 100% for predicting SCLC.Conclusions These results indicate that sputum metabolic profiling may have potential for screening of lung cancer and lung cancer recurrence, and may greatly improve effectiveness of clinical intervention.